Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146990 · ClinicalTrials.gov registry record
A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
A clinical trial, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- 245
- Enrollment target
NCT01146990 is a clinical trial that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 245 participants.
The verdict
NCT01146990 has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- 245 participants
- Enrollment target
Study Summary
In the continuing efforts to understand the benefits and risks of in utero exposure to 17P this study is designed to evaluate differences in developmental outcomes of children, aged 23 to 25 months, born to mothers who participated in the 17P Efficacy Trial sponsored by Hologic (Protocol number 17P-ES-003).
Interventions
- DRUG ASQ-3, Bayley III, Neurologic exam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2010-11-09 |
| Est. Completion | 2020-08-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146990
The ClinicalTrials.gov registry entry for NCT01146990 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASQ-3, Bayley III, Neurologic exam is the first listed.
NCT01146990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01146990 about?
NCT01146990 is a clinical study titled "A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth". In the continuing efforts to understand the benefits and risks of in utero exposure to 17P this study is designed to evaluate differences in developmental outcomes of children, aged 23 to 25 months, born to mothers who participated in the 17P Efficacy Trial sponsored by Hologic (Protocol number 17P-...
What is the current status of trial NCT01146990?
This trial is currently completed. The enrollment target is 245 participants. The study started on 2010-11-09. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT01146990?
The interventions under investigation include: ASQ-3, Bayley III, Neurologic exam (DRUG).
Who is sponsoring clinical trial NCT01146990?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.